Hopital Gui de Chauliac

Montpellier, Herault 34295

0 studies enrolling now · 10 studies all time

What they study most

ALS, Alzheimer's Disease, Alzheimer's Disease Dementia, Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment Due to Alzheimer's Disease, Multiple Sclerosis, Relapsing-Remitting, Narcolepsy, Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), Parkinson Disease, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age — Running, not enrolling
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) — Completed
• A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis — Running, not enrolling
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy — Stopped early
• An Efficacy and Safety Study of Ravulizumab in ALS Participants — Stopped early
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease — Stopped early